Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive

Case Studies

Using Modeling and Simulation to Determine First-in-Human Dose

Background & Problem Nuventra’s client requested assistance using modeling and simulation to determine the First-in-Human (FIH) dose for their program. The drug was created to prevent the toxicity of cytotoxic drugs. However, the sponsor felt that the drug could be studied in healthy volunteers in… Read more

Due Diligence to Support a Client’s Decision-Making

Background & Problem A client needed due diligence performed on the pre-clinical data, translational dose rationale, and first-in-human (FIH) clinical protocol for a central nervous system (CNS) small molecule, indicated for a chronic neurodegenerative orphan disease. Our Solution Pre-clinical Absorption, Distribution, Metabolism, and Excretion (ADME),… Read more

Using PBPK to Extrapolate Animal Tissue Concentrations to Humans

Background & Problem An approved small molecule therapeutic had shown efficacy in numerous target organs of interest in clinical trials. The client wished to show that this efficacy was explained by high drug penetration into these tissues. Our Solution Mouse biodistribution data was collected. A… Read more

End-to-End 505(b)(2) Submission Support

Background & Problem The client needed guidance on their program from start to finish, and there were complications obtaining the reference listed drug (RLD). We engaged the client prior to the IND-enabling program by conducting a gap analysis (US IND and EU IMPD submissions) and… Read more